INVEST 2024
Join us to hear from innovative investors and entrepreneurs offering novel approaches to solve some of healthcare’s greatest challenges.
Join us to hear from innovative investors and entrepreneurs offering novel approaches to solve some of healthcare’s greatest challenges.
AUA 2024, N-803 plus BCG, Non Muscle Invasive Bladder Cancer (NMIBC), BCG Refractory, QUILT 3032 trial, ANKTIVA, interleukin-15 superagonist (IL-15), BCG-unresponsive high-grade NMIBC.
AUA 2024, non-muscle invasive bladder cancer (NMIBC), trans urethral resection of bladder tumor (TURBT), HG T1 bladder cancer, Replacing ReTUR with Cystoscopy, HuNIRe trial, urine cytology,…
AUA 2024 efficacy of repeat BCG challenge in patients with “BCG unresponsive” non-muscle invasive bladder cancer (NMIBC), BCG-unresponsive NMIBC,
Lawmakers have ghost networks in their sights, and payers can prepare now for policy changes.
Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with…
Hospitals’ operating margins and patient volumes dropped slightly in March. While hospitals were doing relatively well financially during the first quarter of the year, this…
AUA 2024 third interim analysis of the DARolutamide ObservationaL (DAROL) study, nonmetastatic castration-resistant prostate cancer (nmCRPC), DAROL study, darolutamide, phase 3 ARAMIS trial.
AUA 2024, muscle-invasive bladder cancer (MIBC), depression in muscle-invasive bladder cancer patients, neoadjuvant chemotherapy (NAC), Effects of Neoadjuvant Chemotherapy on Rates of Depression.
Technological advancements, evolving patient expectations, and global health challenges reshape how healthcare professionals deliver care.
AUA 2024 results of a phase 1 dose-escalation trial of multiple and fractionated-dose PSMA-targeted alpha radionuclide 225Ac-J591, metastatic castration-resistant prostate cancer (mCRPC), advanced prostate cancer.